D-1095-2023 Class III Ongoing
FDA drug recall D-1095-2023 was initiated by Glenmark Pharmaceuticals Inc., USA on Aug 14, 2023 and is designated Class III. Reason for recall: Subpotent: Out of Specification for Assay Test at the 3-month time point. The recall status is ongoing. Affected quantity: 1,200 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 30, 2023
- Initiation Date
- Aug 14, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,200 bottles
Product description
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01
Reason for recall
Subpotent: Out of Specification for Assay Test at the 3-month time point.
Distribution pattern
nationwide in the U.S.
Code information
Batch # 19224744
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1095-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026